Randomized, controlled open-label, pilot study of efficacy and safety of Shigrupatra (Moringa Oleifera lam.leaves) Capsule as an add-on therapy to standard medication in dyslipidemias in rural South Indian tertiary care hospital

Abstract

Introduction: Elevated cholesterol and triglycerides are major risk factors for coronary artery disease. Statins are regarded as standard therapy. Herbal remedies may have a synergistic effect in this condition. Lipid-lowering effect of Moringa Oleifera lam leaves capsule has not been studied in randomized control trials. Methods: In this randomized open-label trial, patients with coronary artery disease between 45 and 75 age group of both gender and elevated triglycerides levels between 150 and 499 mg/dL were randomized. The participants received hypolipidemic medication in the form of 20 mg daily oral rosuvastatin in Group A and 20 mg rosuvastatin and M. Oleifera leaves 2 capsule (400 mg each) at bedtime (Group B) for 6 months as an add-on therapy. The change in triglycerides and high density lipoprotein (HDL) from baseline was the primary outcome measure. Any adverse drug reactions (ADRs) associated with the medication was secondary outcome measure. Result: Final analysis included 44 patients, Group A-control group of 21 and Group B-study group of 23 participants. At the end of 6 months study period there was statistically significant increase in HDL level in Group B, but no significant difference was found in serum triglyceride level in both the Groups. There was no ADR noticed in either group. Conclusion: The findings showed that addition of M. Oleifera leaves capsule as to standard hypolipidemic medication can increase HDL levels in patients with moderate hyperlipidemia. Further research into the efficacy of M. Oleifera leavesin long-term therapy is suggested.

Keywords

• high density lipoproteins
• hypertriglyceridemia
• moringa oleifera linn.
• triglycerides